Nurix Therapeutics (NRIX)
Biotech
Close on Nov 4, 2026 (from our latest article): $15.95
- Market value
- $1.7Bat the Nov 4 close
- Revenue growth
- +739%12 months to Aug 31, 2026 (10-Q)
- FCF margin
- 53%12 months to Aug 31, 2026 (10-Q)
- Net cash
- $1.1Bat Aug 31, 2026
- Worst fall since listing
- −91.5%Jan 19, 2021 to Oct 25, 2023; not back to that high (−72.9% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Nurix Therapeutics
Long-term fundamentals
Annual results for Nurix Therapeutics, FY2019–FY2025, as reported in its 10-K filings. Nurix Therapeutics's fiscal year ends in late November; FY2025 is the year that ended in November 2025.
Revenue and free cash flow
Revenue went from $31M in FY2019 to $84M in FY2025.
Free cash flow was positive in 0 of the 7 years shown; FY2025: −$263M.
Margins
Margins are not charted: in FY2025 the operating loss (−$286M) was larger than revenue ($84M). The table has each year's figures.
Diluted share count
The diluted share count rose 102% from FY2021 to FY2025, to 87M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $84M | — | −340% | −$264M | −$249M | $14M | −$263M |
| FY2024 | $55M | — | −391% | −$194M | −$173M | $9M | −$182M |
| FY2023 | $77M | — | −201% | −$144M | −$81M | $8M | −$90M |
| FY2022 | $39M | — | −476% | −$180M | −$160M | $12M | −$172M |
| FY2021 | $30M | — | −396% | −$117M | −$84M | $6M | −$90M |
| FY2020 | $18M | — | −365% | −$43M | −$0.1M | $5M | −$5M |
| FY2019 | $31M | — | −71% | −$22M | $0.6M | $2M | −$1M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 87M | $593M | — | $38M | — | — |
| FY2024 | 67M | $610M | — | $34M | — | — |
| FY2023 | 54M | $295M | — | $34M | — | — |
| FY2022 | 49M | $309M | — | $28M | — | — |
| FY2021 | 43M | $296M | — | $16M | — | — |
| FY2020 | — | $281M | — | $4M | — | — |
| FY2019 | — | $38M | — | $0.5M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 4, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | NRIX | S&P 500 |
|---|---|---|
| 2019 | — | +31.5% |
| 2020 | +73.0%† | +18.4% |
| 2021 | −11.9% | +28.7% |
| 2022 | −62.1% | −18.1% |
| 2023 | −6.0% | +26.3% |
| 2024 | +82.6% | +25.0% |
| 2025 | +0.7% | +17.9% |
| 2026 to date | −28.3% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (Jul 24, 2020); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- VERA Vera Down 1.2%
- XNCR Xencor Up 15.9%
- VKTX Viking Therapeutics
- ORIC ORIC Pharmaceuticals Down 32%
Show all 17
- SLS SELLAS Up 156.4%
- TNGX Tango Therapeutics Down 16.4%
- IOVA Iovance Down 35.4%
- ARWR Arrowhead Down 15.3%
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- ALNY Alnylam
- GMAB Genmab Up 28.3%
- MRNA Moderna Down 17.6%
Questions about Nurix Therapeutics
- Why did Nurix Therapeutics stock fall on Nov 4, 2026?
- Nurix fell 38% after saying Sanofi will stop the early-stage trial of SAR448272, a drug Nurix discovered, and end the program. Nurix no longer expects about $455 million of possible milestones or any royalties from it. Nurix gave no reason; Leerink Partners said Sanofi's investor relations cited nonclinical findings, BioSpace reported. Nurix says its $1.1 billion of cash still lasts into the second half of 2029. Read the article →